Pyrazinamide News and Research

RSS

Second-line treatment for drug-resistant tuberculosis is as effective as first-line medicines

Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine in New York and GHESKIO Centers in Haiti.

27 Feb 2024

New study reveals turmeric and Tinospora Cordifolia reduce liver injury risk in TB patients

The effectiveness of herbs and alternative medicines in preventing liver injury induced by anti-tuberculosis (anti-TB) drugs.

16 Nov 2023

New hope for TB patients as UNITE4TB launches clinical trial program

Today, UNITE4TB, an international public-private partnership striving to fast-track the development of innovative Tuberculosis (TB) treatments, announced the start of its phase 2B/C clinical trial program with the first participant enrolled at its trial site in Cape Town, South Africa.

13 Nov 2023

New TB treatments tackle the disease without wrecking your microbiome

Researchers in a study published in The Lancet Microbe examined how various tuberculosis treatment regimens affect the respiratory microbiome. They found that certain treatments control tuberculosis effectively while minimally impacting the diversity and health of the respiratory microbiome.

15 Oct 2023

Higher dose and shorter treatment of key antibiotic proven to be safe for TB patients

A higher dose and shorter treatment time of a cornerstone tuberculosis (TB) drug has proven to be safe for patients, according to a clinical trial led by researchers at St George's, University of London and results published in NEJM Evidence.

29 Aug 2023

Clinical trial of three-month TB treatment regimen closed due to high rate of unfavorable outcomes

The first clinical trial of a three-month tuberculosis (TB) treatment regimen is closing enrollment because of a high rate of unfavorable outcomes with the investigational course of treatment.

5 Jul 2023

Real-world management and outcomes of U.S. patients treated with BpaL for rifampin-resistant tuberculosis

Researchers reported on the treatment of rifampin-resistant tuberculosis in the United States using the FDA approved bedaquiline, pretomanid, and linezolid (BPaL) therapy.

1 Jun 2023

Revolution in MDR-TB treatment: Shorter all-oral regimens

Researchers reported on the evolution of multidrug-resistant tuberculosis (MDR-TB) therapy.

6 Apr 2023

Study explores decline in tuberculosis cases during COVID-19 pandemic in the United States

Researchers analyzed a pharmacy dataset to evaluate the 20% decrease in tuberculosis cases reported in 2020 by the US National Tuberculosis Surveillance System.

21 Mar 2022

ACTG announces launch of clinical trial evaluating a three-month TB treatment

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5362 (CLO-FAST), a clinical trial studying a three-month clofazimine- and high-dose rifapentine-containing treatment regimen for people with drug-susceptible tuberculosis (TB).

10 Nov 2021

Study: Four-month regimen of anti-TB drugs works just as well as standard regimen

A new four-month regimen of anti-TB drugs that includes rifapentine and moxifloxacin works just as well as the standard six-month regimen, according to a study.

24 May 2021

Four months of multi-drug therapy for tuberculosis is as effective as standard regimen

Four months of multi-drug therapy that included rifapentine and moxifloxacin treated active tuberculosis (TB) as effectively as the standard six-month regimen in a multinational study, cutting treatment time by a third.

20 May 2021

WHO welcomes SHINE trial results on shorter treatment for drug-susceptible TB in children

The World Health Organization's Global TB Programme welcomes the results from an important study on shortened treatment for drug-susceptible tuberculosis in children, presented at the 51st virtual Union World Conference on Lung Health.

2 Nov 2020

New approach to identify faster, more effective TB drug treatment regimens

Tuberculosis is a potentially deadly though curable disease. Each year about 10 million people develop active cases, and 1.6 million people die. In addition, about 1.7 billion people around the world are infected with TB bacteria, which can lie dormant for weeks to years, then become active and cause disease in up to 10 percent of those who are infected.

15 May 2019

Novel models and strategies for TB detection, elimination, and care

This week, publication of a special issue on tuberculosis begins in PLOS Medicine, advised by guest editors Richard Chaisson of Johns Hopkins University, Claudia Denkinger of the University of Heidelberg, and Mark Hatherill of the South African Tuberculosis Vaccine Institute.

8 Apr 2019

Anti-TB drugs can increase susceptibility to Mtb reinfection

Current treatments for tuberculosis are very effective in controlling TB infection caused by Mycobacterium tuberculosis. They don't, however, always prevent reinfection. Why this happens is one of the long-standing questions in TB research.

22 Mar 2019

Peptide derived from fungi prevents growth of tuberculosis bacteria

The discovery of the peptide as a possible future antibiotic was made when the researchers screened different antimicrobial peptides' ability to prevent the growth of the tuberculosis bacteria Mycobacterium tuberculosis.

4 Mar 2019

Researchers use new methods to optimize treatments for tuberculosis meningitis

Although relatively rare in the United States, and accounting for fewer than 5 percent of tuberculosis cases worldwide, TB of the brain--or tuberculosis meningitis (TBM)--is often deadly, always hard to treat, and a particular threat to young children.

6 Dec 2018

TB Alliance initiates SimpliciTB to test if new four-drug regimen can treat most types of tuberculosis

TB Alliance has initiated a pivotal clinical trial, SimpliciTB, that will evaluate whether a new four-drug regimen can treat most types of tuberculosis including multidrug-resistant TB more quickly and effectively than currently-available treatments.

28 Aug 2018

Higher doses of rifampin kill more TB bacteria in sputum without increasing adverse effects

Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, killed more TB bacteria in sputum cultures, and the higher doses did so without increasing the adverse effects of treatment, according to a randomized controlled trial published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

29 Jun 2018